Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular …
Pfizer doses first patient using investigational mini-dystrophin gene therapyRead More
- Menu
- Skip to right header navigation
- Skip to main content
- Skip to secondary navigation
- Skip to footer
Footer
